Summers Carolyn M, Cucchiara Andrew J, Nackos Eleni, Hammons Andrea L, Mohr Elisabeth, Whitehead Alexander S, Von Feldt Joan M
Department of Pharmacology and Center for Pharmacogenetics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
J Rheumatol. 2008 Nov;35(11):2179-86. doi: 10.3899/jrheum.080071. Epub 2008 Sep 1.
To determine if functional polymorphisms of folate/homocysteine pathway enzymes are associated with homocysteine concentrations and/or coronary artery calcification (CAC) scores in patients with systemic lupus erythematosus (SLE) and controls.
We investigated 163 SLE patients and 160 controls. Functional polymorphisms in 6 genes in the folate/homocysteine pathway were genotyped: 5,10-methylenetetrahydrofolate reductase (MTHFR) 677C>T, MTHFR 1298A>C, cystathionine ss-synthase (CBS) 844ins68, methionine synthase (MTR) 2756A>G, methionine synthase reductase (MTRR) 66A>G, thymidylate synthase (TYMS) 1494del6, and dihydrofolate reductase (DHFR) c.86+60_78.
Homocysteine levels were higher in African American SLE patients than Caucasian patients and African American controls. Genotype distributions were significantly different in African American and Caucasian controls for 6 of the 7 polymorphisms. Genotype distributions for each polymorphism did not differ significantly between SLE patients and controls even after stratification by race. Glomerular filtration rate was strongly negatively correlated to homocysteine levels, and was therefore adjusted for as a covariate in the models of the effects of the polymorphisms on homocysteine levels. In SLE patients none of the 7 polymorphisms was associated with homocysteine concentrations. In Caucasian controls only MTHFR 677C>T and 1298A>C showed effects on homocysteine similar to what would be expected from the literature. There were no genotypic associations with median CAC scores in SLE patients or controls with and without stratification by race.
Polymorphisms in folate/homocysteine metabolizing enzymes do not predict higher homocysteine levels or CAC scores in patients with SLE.
确定叶酸/同型半胱氨酸途径酶的功能多态性是否与系统性红斑狼疮(SLE)患者及对照者的同型半胱氨酸浓度和/或冠状动脉钙化(CAC)评分相关。
我们调查了163例SLE患者和160例对照者。对叶酸/同型半胱氨酸途径中6个基因的功能多态性进行基因分型:5,10-亚甲基四氢叶酸还原酶(MTHFR)677C>T、MTHFR 1298A>C、胱硫醚β-合成酶(CBS)844ins68、甲硫氨酸合成酶(MTR)2756A>G、甲硫氨酸合成酶还原酶(MTRR)66A>G、胸苷酸合成酶(TYMS)1494del6以及二氢叶酸还原酶(DHFR)c.86+60_78。
非裔美国SLE患者的同型半胱氨酸水平高于白种SLE患者以及非裔美国对照者。在7种多态性中的6种,非裔美国对照者和白种对照者的基因型分布存在显著差异。即使按种族分层后,SLE患者和对照者之间每种多态性的基因型分布也没有显著差异。肾小球滤过率与同型半胱氨酸水平呈强烈负相关,因此在多态性对同型半胱氨酸水平影响的模型中作为协变量进行了校正。在SLE患者中,7种多态性均与同型半胱氨酸浓度无关。在白种对照者中,只有MTHFR 677C>T和1298A>C对同型半胱氨酸的影响与文献预期相似。无论是否按种族分层,SLE患者或对照者的中位CAC评分均无基因型关联。
叶酸/同型半胱氨酸代谢酶的多态性不能预测SLE患者较高的同型半胱氨酸水平或CAC评分。